Stronger Effect of Azilsartan on Reduction of Proteinuria Compared to Candesartan in Patients with CKD: A Randomized Crossover Trial

Stronger Effect of Azilsartan on Reduction of Proteinuria Compared to Candesartan in Patients with CKD: A Randomized Crossover Trial

Introduction: Angiotensin receptor blockers (ARBs) are preferably used in hypertensive patients with CKD. Azilsartan is a strong antihypertensive ARB, but its antiproteinuric effects are not well understood. We compared the antiproteinuric effect of azilsartan and candesartan in CKD patients in an o...

Full description

Bibliographic Details
Main Authors: Takaichi Suehiro, Kazuhiko Tsuruya, Hisako Yoshida, Hiroaki Tsujikawa, Shunsuke Yamada, Shigeru Tanaka, Akihiro Tsuchimoto, Masahiro Eriguchi, Kiichiro Fujisaki, Kumiko Torisu, Toshiaki Nakano, Takanari Kitazono
Format: Article
Language:English
Published: Karger Publishers 2021-03-01
Series:Kidney & Blood Pressure Research
Subjects:
azilsartan
candesartan
ckd
crossover trial
proteinuria
Online Access:https://www.karger.com/Article/FullText/512365

Internet

https://www.karger.com/Article/FullText/512365

Similar Items